12929_2019_585_MOESM2_ESM.tif (430.89 kB)
MOESM2 of Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
figure
posted on 2019-11-12, 05:03 authored by An-Ting Liou, Chun-Che Liao, Shu-Fan Chou, Ya-Shu Chang, Chih-Shin Chang, Chiaho ShihAdditional file 2: Figure S2. Inhibition of IFN signaling enhanced EV-A71 infection and pathogenesis. a When treated with IFNAR neutralizing antibody, a trend of more severe paralysis rate was observed. However, no statistical significance was noted between the experimental group treated with neutralizing antibody and the control group treated with mouse IgG antibody. b IFNG (interferon-gamma) antibody was administered on 1, 2, and 3 dpi. Although a trend of more severe paralysis rate was observed, no statistical significance was noted between the experimental group and the control group.